Latest News
SOFIE Biosciences reports first patient dosed Phase 3 clinical trial of [18F]FAPI-74
30 December 2025 - SOFIE Biosciences, a US manufacturer and developer of radiopharmaceuticals, announced on Monday that the first patient has been dosed in one of its two Phase 3 clinical trials evaluating [18F]FAPI-74, a fluorine-18 labeled radiopha...
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
30 December 2025 - Swedish biotechnology company Diamyd Medical AB (Nasdaq First North Growth Market:DMYD-B) said on Monday that it has reached alignment with the US Food and Drug Administration (FDA) to accelerate the primary efficacy readout in its...
INOVIO's INO-3107 Biologics License Application accepted by US FDA
30 December 2025 - Biotechnology company INOVIO (NASDAQ:INO) announced on Monday that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for INO-3107 for review as a potential treatment for adults with Recu...
Tri-City Cardiology adds new members to care team
29 December 2025 - Tri-City Cardiology, a Phoenix, Arizona-based cardiology group, announced on Friday that it has added Dr. Olubadewa A. Fatunde and Dr. Umashankar Lakshmanadoss to its care team.Dr. Fatunde is joining San Tan Valley and Pecos clinic...
ABL Bio receives upfront payment and equity investment from Eli Lilly
29 December 2025 - ABL Bio, a South Korean company specialising in bispecific antibodies, announced on Friday that it will receive an upfront payment of USD40m for a licence, research and collaboration agreement for its Grabody platform, and an equit...